Ranbaxy Laboratories Limited announced that its subsidiary, Ranbaxy Malaysia Sdn Bhd, has launched generic Losartan K 50mg and 100mg tablet in Malaysia.

The company obtained necessary approval from the Drug Control Authority in Malaysia to manufacture and market the product locally.

The market size of Losartan K tablets in Malaysia is US$6.29 million. The product will be marketed under the brand name of Covance and its formulation is bioequivalent to the innovator.Covance tablets are indicated and employed as an antihypertensive.

"We have launched Covance tablets at an affordable price that will benefit the Malaysian healthcare system and bring substantial cost savings to patients. The product will be offered to general practitioners, specialist doctors, pharmacists and hospitals with immediate effect," said Jeyabalan Thangarajah, area director, ASEAN and managing director, Ranbaxy Malaysia.

Ranbaxy's plant in Malaysia has developed this dosage form through the transfer of scientific skills and technology from its R&D center, located in Gurgaon, India. The product will be manufactured at its facility in Malaysia.

Ranbaxy Malaysia Sdn Bhd (RMSB) is a subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RMSB is engaged in the manufacturing, sales and distribution of generic prescription products in the Malaysian Healthcare System.